Verastem Inc (NASDAQ: VSTM) is a commercial-stage oncology biopharmaceutical company that develops and sells targeted cancer therapies. Revenue is generated through product sales of AVMAPKI FAKZYNJA CO-PACK, distributed via specialty pharmacy and specialty distributor channels, with net revenue reduced by trade discounts, allowances, chargebacks, and third-party payer fees. Verastem became a public company on January 27, 2012, and is incorporated in Delaware. As of the fiscal year ended December 31, 2025, the company continued to incur operating losses, with cash used in operating activities of $137.5 million in FY2025 compared to $104.8 million in FY2024. Accumulated losses since inception reflect a pre-profitability stage despite active commercialization. The company has funded operations through equity offerings, convertible preferred stock, debt facilities, and at-the-market programs. No competitors are named in the available filing excerpts.
Source: SEC 10-K, filed 2026-03-04
Industry: Pharmaceutical Preparations Peers: Actinium Pharmaceuticals Inc Acumen Pharmaceuticals Inc Akouos, Inc. Armata Pharmaceuticals Inc Ardelyx Inc LENZ Therapeutics Inc Oyster Point Pharma, Inc. ARS Pharmaceuticals Inc
Loading...